Medicines Co. (MDCO) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company Reports Third-Quarter and First Nine Months 2015 Business and Financial Results
November 3, 2015 7:06 AM ESTFour potential blockbuster development compounds progressing rapidly New hospital product launches progressing Chairman of the Board, Dr. Fred Eshelman, to provide an update on strategy
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced its business and financial results for the third quarter and the nine months ended September 30, 2015.
The Company is developing four potentially class-leading investigational compounds through clinical trials:
1. A PCSK9 inhibitor (ALN-PCSsc) which is emerging as a potential... More
